gnbt - momento da verdade
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Dendreon Receives FDA Approval for Provenge
atenção! a gnbt e a DNDN fazem parte do fundo Mentor Capital - Cancer Immunotherapy Index .
a gnbt está a trabalhar na mesma área que a DNDN(vacina contra o cancro - através do ae37). Com esta aprovação certamente a gnbt vai ser alvo de mais atenção...
wait and see....
atenção! a gnbt e a DNDN fazem parte do fundo Mentor Capital - Cancer Immunotherapy Index .
a gnbt está a trabalhar na mesma área que a DNDN(vacina contra o cancro - através do ae37). Com esta aprovação certamente a gnbt vai ser alvo de mais atenção...
wait and see....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
pedro200 Escreveu:Shevet Escreveu:Compradora???
Tem os cofres limpos na compra e 100k a vender a 0,47
Já nao sei que te diga Pedro, é daqueles titulos que acredito, mas não a curto prazo!!
Não percebi o movimento de hoje, no prorealtime aparece minimo a 0,36 e maximo a 0,51 deve estar errado!!!!!
Ja vai voltar para tras 0,45
abraço
100000 a 0,4720? sim, é verdade! ela vai desaparecer daqui a pouco....
já desapareceu! foi apenas para assustar....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Shevet Escreveu:Compradora???
Tem os cofres limpos na compra e 100k a vender a 0,47
Já nao sei que te diga Pedro, é daqueles titulos que acredito, mas não a curto prazo!!
Não percebi o movimento de hoje, no prorealtime aparece minimo a 0,36 e maximo a 0,51 deve estar errado!!!!!
Ja vai voltar para tras 0,45
abraço
100000 a 0,4720? sim, é verdade! ela vai desaparecer daqui a pouco....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Compradora???
Tem os cofres limpos na compra e 100k a vender a 0,47
Já nao sei que te diga Pedro, é daqueles titulos que acredito, mas não a curto prazo!!
Não percebi o movimento de hoje, no prorealtime aparece minimo a 0,36 e maximo a 0,51 deve estar errado!!!!!
Ja vai voltar para tras 0,45
abraço
Tem os cofres limpos na compra e 100k a vender a 0,47
Já nao sei que te diga Pedro, é daqueles titulos que acredito, mas não a curto prazo!!
Não percebi o movimento de hoje, no prorealtime aparece minimo a 0,36 e maximo a 0,51 deve estar errado!!!!!
Ja vai voltar para tras 0,45
abraço
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
Atenção à GNBT!!!
nas ultimas semanas neste forum chamei a atenção para o congresso de barcelona, onde agnbt fez uma apresentação e para um patente da gnbt. Passado alguns dias (semanas), a gnbt divulgou essa informação. Parece que advinhei?
sorte? talvez...
qual a proxima press release??
- vendas do crave-nx??
- AE37 deal? (sim, espero bem) se acontecer a cotação multiplica por 3 ou 4! estou a sonhar? talvez esteja, mas acho que tenho esse direito! vamos esperar!
longo na gnbt
nas ultimas semanas neste forum chamei a atenção para o congresso de barcelona, onde agnbt fez uma apresentação e para um patente da gnbt. Passado alguns dias (semanas), a gnbt divulgou essa informação. Parece que advinhei?
sorte? talvez...
qual a proxima press release??
- vendas do crave-nx??
- AE37 deal? (sim, espero bem) se acontecer a cotação multiplica por 3 ou 4! estou a sonhar? talvez esteja, mas acho que tenho esse direito! vamos esperar!
longo na gnbt
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
e para não variar aparece o outro a falar mal da gnbt:
http://www.thestreet.com/_yahoo/story/1 ... &cm_ite=NA
http://www.thestreet.com/_yahoo/story/1 ... &cm_ite=NA
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Re: patente - 30 de março de 2010
pedro200 Escreveu:Method for administering insulin to the buccal region
- a gnbt demorou 7 longos anos até conseguir esta patente....
http://patft.uspto.gov/netacgi/nph-Pars ... =7,687,453
Notícia de Hoje
(no dia 25 de abril dei conta desta noticia que, a gnbt só divulgou hoje...) anadam a controlar as press release... porque será?
http://finance.yahoo.com/news/Generex-R ... l?x=0&.v=1
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
O reverse-split é inevitável, pois a GNBT não vai conseguir subir em tão poucos dias para valores acima de 1.00, ainda por cima com o estado dos mercados em geral.
Após a operação do reverse-split as cotações tendem geralmente a continuar a corrigir.
Após a operação do reverse-split as cotações tendem geralmente a continuar a corrigir.
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
Informação - Saiu Hoje!
http://stockreads.com/Stock-Newsletter.aspx?id=24609
StockMarketNewsAlert.com NEW Corporate Stock Alert ~~~~~~~~~~~~~~~~~~~~~~~~~~
GNBT announced Updated Phase I Results From Novel Immunotherapeutic Vaccine Presented at the European Association of Urology Congress today.
We have decent volume and positive upticks. Time to nibble heavy at these levels.
NEW TARGET $1.17 ++++++++++++++++++++++++++++++++ Generex Announces Updated Phase I Results From Novel Immunotherapeutic Vaccine Presented at the European Association of Urology Congress WORCESTER, Mass., April 27, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly owned subsidiary of Generex, for multiple cancer indications. The presentation was made at the 25th Anniversary Congress of the European Association of Urology (EAU) (www.uroweb.org), which was held in Barcelona, Spain from April 16 through April 20.
In addition to safety and the demonstration of a specific immunological response to AE37, it was shown that circulating levels of the extracellular domain of the HER2 protein were decreased in immunized patients compared to pre-vaccine levels.
The AE37 vaccine was designed using a fragment of the HER2 protein and proprietary modifications developed at Antigen Express. The immunity generated by AE37 appeared to be long lasting, as significant vaccine-specific delayed type hypersensitivity (DTH) reactions were still apparent 6 months after the end of vaccinations. These results add to the body of data previously generated showing that AE37 is safe and immunologically active. Interim results from an ongoing Phase II trial of AE37 in breast cancer patients indicated that there were fewer recurrences in patients receiving AE37.
The EAU represents the leading authority within Europe on urological practice, research and education. Over 13,000 medical professionals have joined its ranks and help to create forward-looking solutions for continuous improvement, professional growth, and knowledge sharing.
The EAU delivers training, stimulates research, and broadcasts information. The EAU`s scientific publications encourage discussion and its expert recommendations guide urologists in their every-day practice.
About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Generex Oral-lyn(TM)), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express
http://stockreads.com/Stock-Newsletter.aspx?id=24609
StockMarketNewsAlert.com NEW Corporate Stock Alert ~~~~~~~~~~~~~~~~~~~~~~~~~~
GNBT announced Updated Phase I Results From Novel Immunotherapeutic Vaccine Presented at the European Association of Urology Congress today.
We have decent volume and positive upticks. Time to nibble heavy at these levels.
NEW TARGET $1.17 ++++++++++++++++++++++++++++++++ Generex Announces Updated Phase I Results From Novel Immunotherapeutic Vaccine Presented at the European Association of Urology Congress WORCESTER, Mass., April 27, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly owned subsidiary of Generex, for multiple cancer indications. The presentation was made at the 25th Anniversary Congress of the European Association of Urology (EAU) (www.uroweb.org), which was held in Barcelona, Spain from April 16 through April 20.
In addition to safety and the demonstration of a specific immunological response to AE37, it was shown that circulating levels of the extracellular domain of the HER2 protein were decreased in immunized patients compared to pre-vaccine levels.
The AE37 vaccine was designed using a fragment of the HER2 protein and proprietary modifications developed at Antigen Express. The immunity generated by AE37 appeared to be long lasting, as significant vaccine-specific delayed type hypersensitivity (DTH) reactions were still apparent 6 months after the end of vaccinations. These results add to the body of data previously generated showing that AE37 is safe and immunologically active. Interim results from an ongoing Phase II trial of AE37 in breast cancer patients indicated that there were fewer recurrences in patients receiving AE37.
The EAU represents the leading authority within Europe on urological practice, research and education. Over 13,000 medical professionals have joined its ranks and help to create forward-looking solutions for continuous improvement, professional growth, and knowledge sharing.
The EAU delivers training, stimulates research, and broadcasts information. The EAU`s scientific publications encourage discussion and its expert recommendations guide urologists in their every-day practice.
About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Generex Oral-lyn(TM)), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Bean_Jr Escreveu:o link em baixo diz que ela vai para o céu ....
"Generex Biotechnology Corporation (NASDAQ:GNBT) has the 1st highest upside potential in this segment of the market. Its upside is 1233.3%. Its consensus target price is $6.00 based on the average of all estimates"
http://www.cnanalyst.com/2010/04/top-10 ... 7-201.html
é como mandar uma moeda ao ar....
cumprimentos
eu conheço esse site!
vamos lá ver se acertam...
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
o link em baixo diz que ela vai para o céu ....
"Generex Biotechnology Corporation (NASDAQ:GNBT) has the 1st highest upside potential in this segment of the market. Its upside is 1233.3%. Its consensus target price is $6.00 based on the average of all estimates"
http://www.cnanalyst.com/2010/04/top-10 ... 7-201.html
é como mandar uma moeda ao ar....
cumprimentos
"Generex Biotechnology Corporation (NASDAQ:GNBT) has the 1st highest upside potential in this segment of the market. Its upside is 1233.3%. Its consensus target price is $6.00 based on the average of all estimates"
http://www.cnanalyst.com/2010/04/top-10 ... 7-201.html
é como mandar uma moeda ao ar....
cumprimentos
Bons negocios
-
- Mensagens: 157
- Registado: 17/3/2009 21:55
- Localização: Lisboa
Shevet Escreveu:Até la ..............vamos andando nisto meu caro!!
As noticias são positivas, mas os mercados é que mandam.......!!!
Isto ja não mexe com estas noticias, tem de sair mesmo uma nova aprovação.
Abraço
Shevet
ou com o anuncio de uma parceria para o AE37....
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
não quero especular mas:
- não custuma ser muito normal aquilo que se está a passar nos cofres da gnbt! não custuma ser habitual esta pressão no lado da compra....
caso os administradores considerem este post especulativo, agradeço que o apaguem.
cumprimentos e bons trades
- não custuma ser muito normal aquilo que se está a passar nos cofres da gnbt! não custuma ser habitual esta pressão no lado da compra....
caso os administradores considerem este post especulativo, agradeço que o apaguem.
cumprimentos e bons trades
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Até la ..............vamos andando nisto meu caro!!
As noticias são positivas, mas os mercados é que mandam.......!!!
Isto ja não mexe com estas noticias, tem de sair mesmo uma nova aprovação.
Abraço
Shevet
As noticias são positivas, mas os mercados é que mandam.......!!!
Isto ja não mexe com estas noticias, tem de sair mesmo uma nova aprovação.
Abraço
Shevet
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
StockMarketNewsAlert.com NEW Corporate Stock Alert ~~~~~~~~~~~~~~~~~~~~~~~~~~
GNBT is still waiting on the upside break. We may get it soon.
GNBT is slowly building momentum similiar to the way GOIG started out.
Get on board GNBT before its too late.
The 52-week high for GNBT is $1.14. This stock could approach or break that high near-term.
++++++++++++++++++++++++++++++++++++++ Generex Biotechnology is positioning itself as the leading bioscience company and is engaged in the research, development and commercialization of drug deliverysystems and technologies.
Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).
GNBT is still waiting on the upside break. We may get it soon.
GNBT is slowly building momentum similiar to the way GOIG started out.
Get on board GNBT before its too late.
The 52-week high for GNBT is $1.14. This stock could approach or break that high near-term.
++++++++++++++++++++++++++++++++++++++ Generex Biotechnology is positioning itself as the leading bioscience company and is engaged in the research, development and commercialization of drug deliverysystems and technologies.
Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Quem está ligado:
Utilizadores a ver este Fórum: aaugustobb_69, Akinfiev, Apramg, Ferreiratrade, iniciado1, latbal, m-m, malakas, Manchini888, OCTAMA, Olhar Leonino, PacoNasssa, peterteam2, Shimazaki_2, trilhos2006 e 168 visitantes